(Total Views: 143)
Posted On: 07/15/2024 4:18:02 PM
Post# of 48
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes.
Nutriband’s proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is working with Kindeva Drug Delivery to complete the scale-up of the commercial manufacturing process for AVERSA Fentanyl. The two companies started with a feasibility agreement and have since entered a commercial-development and clinical-supply agreement aimed at manufacturing product for a planned human-abuse potential clinical study, which is crucial for the New Drug Application (“NDA”) that the company anticipates submitting to the U.S. Food and Drug Administration. “AVERSA aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles,” said the company in the press release. “The AVERSA technology is supported by a robust intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico and Australia. . . . The AVERSA(TM) trademark is integral to Nutriband’s platform technology, which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential.”
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at http://nnw.fm/NTRB
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes.
Nutriband’s proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is working with Kindeva Drug Delivery to complete the scale-up of the commercial manufacturing process for AVERSA Fentanyl. The two companies started with a feasibility agreement and have since entered a commercial-development and clinical-supply agreement aimed at manufacturing product for a planned human-abuse potential clinical study, which is crucial for the New Drug Application (“NDA”) that the company anticipates submitting to the U.S. Food and Drug Administration. “AVERSA aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles,” said the company in the press release. “The AVERSA technology is supported by a robust intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico and Australia. . . . The AVERSA(TM) trademark is integral to Nutriband’s platform technology, which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential.”
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at http://nnw.fm/NTRB
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
